Cresco Labs Inc. (OTCMKTS:CRLBF – Free Report) – Atb Cap Markets boosted their FY2025 EPS estimates for shares of Cresco Labs in a report released on Monday, December 9th. Atb Cap Markets analyst F. Gomes now expects that the company will post earnings of ($0.07) per share for the year, up from their prior forecast of ($0.09). Atb Cap Markets has a “Hold” rating on the stock. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.20) per share.
Several other research analysts also recently weighed in on the stock. Roth Capital raised shares of Cresco Labs to a “strong-buy” rating in a research report on Sunday, November 10th. Cormark downgraded shares of Cresco Labs from a “moderate buy” rating to a “hold” rating in a research note on Monday, November 11th. Four equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $2.50.
Cresco Labs Trading Down 3.3 %
Shares of Cresco Labs stock opened at $1.04 on Wednesday. The firm has a market cap of $507.67 million, a price-to-earnings ratio of -5.20 and a beta of 1.73. Cresco Labs has a fifty-two week low of $1.02 and a fifty-two week high of $2.65. The business has a fifty day simple moving average of $1.39 and a 200-day simple moving average of $1.58. The company has a quick ratio of 1.39, a current ratio of 1.97 and a debt-to-equity ratio of 1.80.
About Cresco Labs
Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.
Further Reading
- Five stocks we like better than Cresco Labs
- Want to Profit on the Downtrend? Downtrends, Explained.
- 4 Stocks Planning to Return Capital With Hefty Buyback Programs
- How to Capture the Benefits of Dividend Increases
- Overblown Holiday Worries? 3 Stocks Set for a Surprise Comeback
- 3 Small Caps With Big Return Potential
- UiPath: A Golden Opportunity in AI-Driven Workflow Automation
Receive News & Ratings for Cresco Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cresco Labs and related companies with MarketBeat.com's FREE daily email newsletter.